ArticleThe Journal of general physiology2026
Brain voltage-gated Ca2+ channels and calmodulin: Teaming up in calmodulinopathies?
Article in The Journal of general physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
Calmodulin (CaM) serves as one of the key cellular Ca2+ sensors with >300 targets and a highly conserved structure since its appearance in early eukaryogenesis. Three distinct CaM genes (CALM1, CALM2, and CALM3) encode one identical CaM protein in mammals. This low tolerance for structural changes highlights that CaM mutations are likely not well tolerated and therefore cause disease in humans. The first calmodulinopathies reported were catecholaminergic polymorphic ventricular tachycardia (CPVT) and a severe, early-onset cardiac arrhythmia syndrome with long-QT syndrome (LQTS). This led to recognition that CaM-modulated cardiac Cav1.2 L-type Ca2+ channels and RYR2 ryanodine receptors are key targets mediating the severe cardiac phenotype of CaM mutants . In this issue of the JGP, Hussey et al. (https://doi.org/10.1085/jgp.202413734) addressed the important question of whether dysregulation of voltage-gated Ca2+ channels in the brain could contribute to neurological/neurodevelopmental symptoms that are also associated with calmodulinopathies.
Indexed as
Identifiers
42126403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.